# Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

> **NCT06577987** · PHASE1 · RECRUITING · sponsor: **Circle Pharma** · enrollment: 220 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Metastatic Solid Tumor
- Refractory Solid Tumor
- Cancer
- Lung Cancer
- Triple Negative Breast Cancer
- Breast Neoplasms
- Neuroendocrine Tumors
- Neuroendocrine Carcinoma
- RB1 Gene Mutation

## Interventions

- **DRUG:** CID-078 Monotherapy

## Key facts

- **NCT ID:** NCT06577987
- **Lead sponsor:** Circle Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-14
- **Primary completion:** 2027-01-14
- **Final completion:** 2027-03-14
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06577987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06577987, "Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06577987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*